Medpace (NASDAQ:MEDP) Shares Unloaded Rep. Lisa C. McClain

Key Points

• Representative Lisa C. McClain sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP), disclosing a transaction between $1,001 and $15,000 on August 4th, 2025.
• The company's stock dropped by 1.1%, opening at $490.77, with a market cap of $13.79 billion and a PE ratio of 36.49.
• Analysts have mixed opinions on Medpace, with ratings ranging from Buy to Sell and an average price target of $422.27.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Medpace Holdings, Inc. NASDAQ: MEDP. In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on August 4th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of ACI Worldwide NASDAQ: ACIW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Amedisys NASDAQ: AMED on 8/18/2025.
• Purchased $1,001 - $15,000 in shares of Kite Realty Group Trust NYSE: KRG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of JD.com NASDAQ: JD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of US Foods NYSE: USFD on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Agree Realty NYSE: ADC on 8/13/2025.

Medpace Trading Down 0.7%

NASDAQ MEDP traded down $3.34 on Friday, hitting $498.60. 744,026 shares of the company's stock were exchanged, compared to its average volume of 295,741. The stock has a 50-day moving average of $446.89 and a 200-day moving average of $355.06. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $506.55. The stock has a market cap of $14.01 billion, a price-to-earnings ratio of 37.07, a P/E/G ratio of 3.16 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same period in the prior year, the company earned $2.75 EPS. Medpace's revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Institutional Trading of Medpace

Large investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group grew its stake in shares of Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after buying an additional 71 shares during the period. Whittier Trust Co. grew its stake in shares of Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares during the period. Employees Retirement System of Texas acquired a new stake in shares of Medpace in the 2nd quarter valued at about $36,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in Medpace in the 1st quarter valued at about $60,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel owned 10,343 shares of the company's stock, valued at $4,654,350. This trade represents a 22.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 161,266 shares of company stock worth $74,111,427. Corporate insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of research reports. Barclays increased their price target on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Robert W. Baird increased their price target on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Mizuho increased their price target on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Rothschild Redb cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Finally, UBS Group lowered Medpace from a "neutral" rating to a "sell" rating and raised their target price for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and a consensus price target of $422.27.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.